Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand

Table 3 Input parameters (i.e. utility parameters and characteristics of HIV vaccine) used in Markov model

Parameters	Distribution	Mean	SE	References
Utility parameters
Utility of HIV negative		1
Utility of asymptomatic patients	Beta	0.86	0.01	[24]
Utility of symptomatic patients	Beta	0.80	0.01	[24]
Utility of AIDS patients	Beta	0.76	0.01	[24]
Characteristics of HIV vaccine
Vaccine efficacy	Gamma	31%	13%	[11]
Increased incidences of HIV infection compared to baseline due to the change of risk behaviors	Gamma	20%*	20%*
Duration of booster doses (year)	Gamma	10*	10*

ISSN: 1471-2458